CDEK by Data4ThePeople
IndicationsMechanismsTrialsFDA ApprovalsAbout
Sign in Sign up
IndicationsMechanismsTrialsFDA ApprovalsAbout
← Mechanisms of action

Ephrin receptor

PROTEIN FAMILYHomo sapiens
Children:EPHB2EPHA2EPHA3EPHA8EPHA5EPHB1EPHA4EPHA7EPHA6EPHB4EPHB3EPHA1EPHB6

Linked proteins

  • Ephrin type-A receptor 2 (EPHA2) ↗
  • Ephrin type-B receptor 2 (EPHB2) ↗
  • Ephrin type-A receptor 5 (EPHA5) ↗
  • Ephrin type-A receptor 4 (EPHA4) ↗
  • Ephrin type-A receptor 8 (EPHA8) ↗
  • Ephrin type-A receptor 6 (EPHA6) ↗
  • Ephrin type-A receptor 7 (EPHA7) ↗
  • Ephrin type-B receptor 3 (EPHB3) ↗
  • Ephrin type-A receptor 3 (EPHA3) ↗
  • Ephrin type-B receptor 1 (EPHB1) ↗
  • Ephrin type-B receptor 4 (EPHB4) ↗
  • Ephrin type-A receptor 1 (EPHA1) ↗
  • Ephrin type-B receptor 6 (EPHB6) ↗
  • Ephrin type-A receptor 10 (EPHA10) ↗

Drugs acting on this target (1)

Active Pharmaceutical Ingredient Mechanism Type ▲ Approval Status API Type Mechanism of Action
vandetanib (caprelsa)InhibitorapprovedSmall moleculeEphrin receptor inhibitor

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.